We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-29.4%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$106M
AUM Growth
-$49.2M
Cap. Flow
+$4.09M
Cap. Flow %
3.87%
Top 10 Hldgs %
82.96%
Holding
60
New
6
Increased
11
Reduced
8
Closed
8

Top Buys

Rank Stock Value
1
EQM
EQM Midstream Partners, LP
EQM
+$2.38M
2
CELG
Celgene Corp
CELG
+$2.13M
3
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$1.24M
4
QDEL icon
QuidelOrtho
QDEL
+$782K
5
NBIX icon
Neurocrine Biosciences
NBIX
+$671K

Top Sells

Rank Stock Value
1
CFRX
ContraFect Corporation
CFRX
+$1.1M
2
EQT icon
EQT Corp
EQT
+$938K
3
OVV icon
Ovintiv
OVV
+$629K
4
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$397K
5
AXGN icon
Axogen
AXGN
+$369K

Sector Composition

Rank Sector Weight
1 Healthcare 95.72%
2 Energy 3.02%
3 Materials 0.13%
4 Industrials 0.12%
5 Consumer Staples 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PXD
26
DELISTED
Pioneer Natural Resource Co.
PXD
$500K 0.47%
3,800
+800
+27% +$122K
DRNA
27
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$481K 0.46%
45,000
– –
XNCR icon
28
Xencor
XNCR
$1.4B
$445K 0.42%
12,300
– –
ICPT
29
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$433K 0.41%
4,300
– –
ARVN icon
30
Arvinas
ARVN
$517M
$386K 0.37%
30,000
– –
CFRX
31
DELISTED
ContraFect Corporation
CFRX
$368K 0.35%
300
-696
-70% -$1.1M
FOLD
32
DELISTED
Amicus Therapeutics
FOLD
$364K 0.34%
38,000
– –
CLR
33
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$322K 0.3%
+8,000
New +$409K
OVV icon
34
Ovintiv
OVV
$16.5B
$320K 0.3%
11,060
-14,600
-57% -$629K
NKTR icon
35
Nektar Therapeutics
NKTR
$2.22B
$312K 0.3%
633
– –
VYGR icon
36
Voyager Therapeutics
VYGR
$187M
$310K 0.29%
33,000
– –
DOVA
37
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$303K 0.29%
40,000
+10,000
+33% +$161K
MYGN icon
38
Myriad Genetics
MYGN
$559M
$291K 0.28%
10,000
– –
GTHX
39
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$287K 0.27%
15,000
– –
ODT
40
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$282K 0.27%
20,000
– –
EQT icon
41
EQT Corp
EQT
$30.8B
$213K 0.2%
11,300
-46,198
-80% -$938K
AMAG
42
DELISTED
AMAG Pharmaceuticals
AMAG
$152K 0.14%
+10,000
New +$191K
LTHM
43
DELISTED
Livent Corporation
LTHM
$138K 0.13%
+10,000
New +$163K
LXRX icon
44
Lexicon Pharmaceuticals
LXRX
$1.03B
$133K 0.13%
+20,000
New +$162K
OMED
45
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$129K 0.12%
172,557
+53,868
+45% +$81.1K
SITO
46
DELISTED
SITO MOBILE, LTD
SITO
$126K 0.12%
140,000
– –
IMGN
47
DELISTED
Immunogen Inc
IMGN
$106K 0.1%
+22,000
New +$133K
YTEN
48
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$97K 0.09%
127
-155
-55% -$189K
GNMX
49
DELISTED
Aevi Genomic Medicine Inc
GNMX
$90K 0.09%
128,000
– –
CYTK icon
50
Cytokinetics
CYTK
$10.9B
$63K 0.06%
10,000
– –
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2018 Portfolio in Review

As of Q4 2018, Birchview Capital held 60 positions worth $106M, down 32% from $155M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Birchview Capital deployed $4.09M of net new capital in Q4 2018, opening 6 new positions and adding to 11 existing holdings. Its largest new stake was EQM Midstream Partners, LP: 50,000 shares worth $2.16M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Energy and Materials.

On the sell side, the largest reduction was ContraFect Corporation, an estimated $1.1M trimmed.

  • Birchview Capital's largest Q4 2018 buy was EQM Midstream Partners, LP: 50,000 shares worth $2.16M.
  • Birchview Capital added most to Celgene Corp in Q4 2018, an estimated $2.13M increase.
  • Birchview Capital's biggest Q4 2018 reduction was ContraFect Corporation, cutting an estimated $1.1M.
  • Birchview Capital fully exited AVEO Pharmaceuticals, Inc. in Q4 2018, selling an estimated $397K.
  • Birchview Capital's ten largest holdings make up 83% of its $106M portfolio in Q4 2018.
  • Birchview Capital opened 6 new positions and closed 8 in Q4 2018.
  • Birchview Capital's portfolio value fell 32% quarter-over-quarter to $106M.

Based on Birchview Capital's 13F filing for Q4 2018, filed 6 Feb 2019.